ValiRx plc (VAL.L)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | £m | -2 | -2 | ||||||
| Net profit | £m | -1 | -2 | -2 | -2 | -2 | -2 | -2 | - |
| EPS reported | £ | -0.01 | -0.00 | ||||||
| Operating cashflow per share | £ | -0.00 | -0.00 | ||||||
| Capex per share | £ | 0.00 | 0.00 | ||||||
| FCF per share | £ | -0.00 | -0.00 | ||||||
| Free cash flow | £m | -2 | -1 | ||||||
| Net debt | £m | -1 | -1 | ||||||
| Book value equity | £m | 3 | 3 | ||||||
| Book value per share | £ | 0.01 | 0.00 | ||||||
| Number of shares | m | 413.52 | 838.51 | ||||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 0.49 | 0.44 | ||||||
| P/S LTM | x | 44.16 | 42.40 | ||||||
| P/FCF LTM | x | -0.91 | -1.02 | ||||||
| EV/EBITDA LTM | x | -0.27 | -0.37 | ||||||
| EV/Sales LTM | x | 18.97 | -6.26 | ||||||
| Earnings Yield LTM | % | -1.61% | -2.03% | ||||||
| FCF Yield | % | -109.99% | -98.14% | ||||||
| Quality | |||||||||
| ROE | % | -78.18% | -70.79% | ||||||
| ROIC | % | -72.03% | -72.03% | ||||||
| Operating margin | % | -58.09% | -58.09% | ||||||
| Gross margin | % | -19.92% | -4.08% | ||||||
| FCF/Sales | % | -4856.9% | -4857.1% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -36.97% | -34.36% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -1,092.27 | - | ||||||
| Net Debt/EBITDA | x | 0.36 | 0.46 | ||||||
| EBIT/Net interest | x | -547.62 | -547.62 | ||||||
| Net debt/market cap | % | +0.10% | +0.23% | ||||||
| Net debt/Equity | x | -0.28 | -0.31 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free